It has been observed that there is a statistically significant overexpression of the mRNA levels of SKA1, SKA2, and SKA3 in tumors as compared to normal tissues of patients with glioma included in the UALCAN database using Wilcoxon rank sum tests (p < 0.01; Figure 2). This evidence concerns the gene SKA3 and glioma.